Comprehensive eye exams are vital for detecting early signs of systemic diseases like diabetes, hypertension, and high ...

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...

This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...

Analysis - Drugs such as Ozempic, Wegovy and Mounjaro (known as semaglutide and tirzepatide) have changed the way clinicians manage diabetes and obesity around the world.

Fully autonomous screening for diabetic retinopathy is coming to pharmacies and other locations through a strategic ...

This study is significant as it explores a potential new treatment option for diabetic retinopathy, a leading cause of blindness. The intervention tested was EYP-1901, a Tyrosine Kinase Inhibitor, ...

However, left untreated, diabetic retinopathy will steadily get worse over time and start to affect your vision. Treatment can help prevent, delay, and reduce vision loss.

Diabetic retinopathy, a type of diabetic eye disease, is one of the leading causes of blindness in the United States. Despite this, almost 40% of people with diabetes don’t get an annual eye exam.

Diabetic retinopathy and diabetic macular edema (DME) are two of the most common vision conditions related to diabetes. They affect about 1 in 4 people with type 1 and type 2 diabetes.